| CERo Therapeutics [CERO] - Last Close: $2.55 This tiny biotech is skyrocketing after publishing promising clinical research supporting CER-1236 as a treatment for leukemia patients. CERo outlined its findings in a paper titled Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia (AML) published in Clinical Cancer Research medical journal. The study found that CER-1236 “ effectively eliminated leukemic cells in the company’s experiments.“ CERo says its findings support a Phase 1 trial for AML and, potentially, additional therapeutic options for the drug. CERO is up 668.2% on almost a million shares traded. My Take: CERO is seeing enormous gains as a result of this news, but it almost seems too good to be true. Watch for a pull back. Lytus Technologies [LYT] - Last Close: $2.31 After Wednesday’s close, Lotus Technologies announced the launch of a suite of cloud infrastructure services it’s calling the Lytus Cloud. The company says the announcement marks their entrance into the “$326 billion data center market.” LYT is soaring in today’s premarket. It’s up 208.2% on roughly 5 million shares traded. My Take: LYT has a very high short ratio, so I suspect this move is more the result of a short squeeze than the aforementioned news. Brera Holdings [BREA] - Last Close: $1.02 A recent regulatlory disclosure revealed that Brera’s executive chairman and veteran investment banker Daniel McClory has acquired a majority stake. According to the filing, McClory recently acquired 4.6 million shares of stock, bringing his total ownership stake to nearly 55%. He also controls 84% of the company’s total votes. BREA is up 124.5% on over 15 million shares traded. My Take: McClory’s buying spree could indicate he has plans for BREA. Investors could be positioning themselves for a potential buyout or take-private deal sometime in this stocks future. Immuron [IMRN] - Last Close: $1.65 Positive interim top-line data from a Phase 2 trial of IMM-124E (Travelan®) is lifting shares of this tiny biotech this morning. Immuron said the trial produced statistically significant results in several key categories, and the data supports advancement to a Phase 3 trial. The company will now hold an end-of-Phase 2 meeting with the FDA to discuss the pivotal Phase 3 registration strategy and clinical trial plans. IMRN is a top mover with a 94.2% gain on roughly 6 million shares traded. My Take: IMRN looks like it’s on its way to an approval, but it could take a while for the next catalyst to develop. Gainers Beneficient [BENF] >> +66.5% Immunoprecise [IPA] >> +36.0% Honest Company [HNST] >> +40.3% Decliners Avid Biosciences [CDMO] >> (32.7%) Solowin [SWIN] >> (33.7%) Victoria’s Secret [VSCO] >> (30.1%) Kroger [KR] ... Am Burlington Stores [BURL] ... AM BJ's Wholesale Club Holdings [BJ] ... AM Toro [TTC] ... AM Broadcom [AVGO] ... PM Costco Wholesale [COST] ... PM MongoDB [MDB] ... PM Samsara [IOT] ... PM DocuSign [DOCU] ... PM Guidewire Software [GWRE] ... PM Initial jobless claims [Mar] ... 8:30aU.S. productivity (revision) [Q4] ... 8:30aU.S. trade balance [Jan] ... 8:30aFed Chair Jerome Powell testifies to Congress ... 9:40aCleveland Fed President Loretta Mester speaks ... 11:30aConsumer credit [Jan] ... 3:00p | 